重大疾病临床研究组建“航母”,提升临床研究能力

2017-07-22 MedSci MedSci原创

围绕心血管疾病、恶性肿瘤、呼吸系统疾病等11个疾病领域建设起32个国家临床医学研究中心,依托30家相应疾病防控领域实力最强、水平最高的三甲医院,联合约260个地级市的2100余家的各级医疗机构,组建高水平临床研究平台和协同创新“航母编队”……自2012年以来,经过4年多的探索实践,我国重大疾病临床研究的“国家队”逐步形成。不仅在提升临床研究能力、加快临床转化方面取得实效,也在加速医药产品创新、系统

围绕心血管疾病、恶性肿瘤、呼吸系统疾病等11个疾病领域建设起32个国家临床医学研究中心,依托30家相应疾病防控领域实力最强、水平最高的三甲医院,联合约260个地级市的2100余家的各级医疗机构,组建高水平临床研究平台和协同创新“航母编队”……

自2012年以来,经过4年多的探索实践,我国重大疾病临床研究的“国家队”逐步形成。不仅在提升临床研究能力、加快临床转化方面取得实效,也在加速医药产品创新、系统性破解医疗服务供给不足等难点问题上取得进展。

长期以来,我国医学研究布局重基础轻临床,临床研究布局薄弱,创新平台“几乎空白”,临床循证产出不足问题突出。医疗资源分布“碎片化”,诊疗水平“参差不齐”,医药产品创新少、转化慢。

“卫生健康是与广大人民群众息息相关的重要民生领域,是科技创新的重要着力点和落脚点。”科技部党组书记、副部长王志刚说,“要充分发挥国家临床医学研究中心主体责任和使命担当,凝心聚力解决临床医学与生命科学、生物技术研究脱节,科学研究的成果不能很好地转化为临床医学应用等难题。”

科技部、国家卫生计生委、中央军委后勤保障部和国家食品药品监督管理总局7月22日在京联合召开国家临床医学研究中心建设工作推进会,发布《国家临床医学研究中心五年(2017-2021年)发展规划》《国家临床医学研究中心管理办法(2017年修订)》和《国家临床医学研究中心运行绩效评估方案》,为国家临床医学研究中心的进一步建设发展、规范管理、科学评价提供指导依据。

主管部门为32个国家临床医学研究中心授牌,为第一届专家咨询委员会的专家们颁发聘书。胡盛寿、钟南山和樊代明三位院士分别介绍了临床中心建设的成绩和经验。

国家卫生计生委副主任曾益新表示,国家临床医学研究中心要突出医学科技创新龙头、科技成果转化枢纽、先进技术辐射光源、创新人才培训基地的功能和定位,强化多方协同,在应对防治重大疾病挑战,以中国式办法破解医改世界性难题,建设健康中国、加快培育和发展健康产业等方面发挥积极作用。

据悉,四部门接下来将大力加强国家临床医学研究中心的建设和管理工作。根据疾病防治的实际需求,进一步加强国家临床医学研究中心按不同疾病种类和不同区域的布局建设,并对已建国家临床医学研究中心实施科学、规范管理,建立动态评估调整机制。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (20)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1801140, encodeId=cd15180114056, content=<a href='/topic/show?id=76b5e3439fc' target=_blank style='color:#2F92EE;'>#研究能力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73439, encryptionId=76b5e3439fc, topicName=研究能力)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Wed Aug 16 19:33:00 CST 2017, time=2017-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=225950, encodeId=52cc225950fe, content=不错的文章,值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04f22055142, createdName=131****2916, createdTime=Mon Jul 24 22:40:32 CST 2017, time=2017-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1628939, encodeId=e16a162893961, content=<a href='/topic/show?id=c27a95e7106' target=_blank style='color:#2F92EE;'>#重大疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95771, encryptionId=c27a95e7106, topicName=重大疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c95421243926, createdName=雕雕, createdTime=Mon Jul 24 13:33:00 CST 2017, time=2017-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=225562, encodeId=a45222556203, content=不错的文章,值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04f22055142, createdName=131****2916, createdTime=Sun Jul 23 22:35:34 CST 2017, time=2017-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=225498, encodeId=f5c922549815, content=不错的文章,值得一看, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Sun Jul 23 16:29:22 CST 2017, time=2017-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=225365, encodeId=6a992253657e, content=中心建设不断延展, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/04/24/1c2dbd6706e64df33befd6663f1d6b37.jpg, createdBy=94f61661779, createdName=lyh994, createdTime=Sun Jul 23 09:44:30 CST 2017, time=2017-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=225353, encodeId=7ed022535371, content=自2012年以来,经过4年多的探索实践,我国重大疾病临床研究的“国家队”逐步形成。不仅在提升临床研究能力、加快临床转化方面取得实效,也在加速医药产品创新、系统性破解医疗服务供给不足等难点问题上取得进展。, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3wrgsNyr5lh6N2MY5xSnbvo4g5sRlc3MZoDdWpMeSdozUCPNhA96wndwQe3X5Z5oYMNxVUdOib63nw/0, createdBy=d8d11998754, createdName=Julie W, createdTime=Sun Jul 23 09:29:02 CST 2017, time=2017-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=225342, encodeId=baac22534296, content=根据疾病防治的实际需求,进一步加强国家临床医学研究中心按不同疾病种类和不同区域的布局建设,并对已建国家临床医学研究中心实施科学、规范管理,建立动态评估调整机制。, beContent=null, objectType=article, channel=null, level=null, likeNumber=14, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7cJ6ejWUr2nIia8qOvAKNdLHr32Df6G8iaoaOx6pHaoiacwp26DaslxZHCGbibZhhCGven4rvmWP60GahtzgFjgCjR/0, createdBy=6b111703011, createdName=有备才能无患, createdTime=Sun Jul 23 09:20:22 CST 2017, time=2017-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=225326, encodeId=c07422532675, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Sun Jul 23 08:38:33 CST 2017, time=2017-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=225302, encodeId=356022530281, content=好东西学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=92191944782, createdName=thlabcde, createdTime=Sun Jul 23 07:51:43 CST 2017, time=2017-07-23, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1801140, encodeId=cd15180114056, content=<a href='/topic/show?id=76b5e3439fc' target=_blank style='color:#2F92EE;'>#研究能力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73439, encryptionId=76b5e3439fc, topicName=研究能力)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Wed Aug 16 19:33:00 CST 2017, time=2017-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=225950, encodeId=52cc225950fe, content=不错的文章,值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04f22055142, createdName=131****2916, createdTime=Mon Jul 24 22:40:32 CST 2017, time=2017-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1628939, encodeId=e16a162893961, content=<a href='/topic/show?id=c27a95e7106' target=_blank style='color:#2F92EE;'>#重大疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95771, encryptionId=c27a95e7106, topicName=重大疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c95421243926, createdName=雕雕, createdTime=Mon Jul 24 13:33:00 CST 2017, time=2017-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=225562, encodeId=a45222556203, content=不错的文章,值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04f22055142, createdName=131****2916, createdTime=Sun Jul 23 22:35:34 CST 2017, time=2017-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=225498, encodeId=f5c922549815, content=不错的文章,值得一看, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Sun Jul 23 16:29:22 CST 2017, time=2017-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=225365, encodeId=6a992253657e, content=中心建设不断延展, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/04/24/1c2dbd6706e64df33befd6663f1d6b37.jpg, createdBy=94f61661779, createdName=lyh994, createdTime=Sun Jul 23 09:44:30 CST 2017, time=2017-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=225353, encodeId=7ed022535371, content=自2012年以来,经过4年多的探索实践,我国重大疾病临床研究的“国家队”逐步形成。不仅在提升临床研究能力、加快临床转化方面取得实效,也在加速医药产品创新、系统性破解医疗服务供给不足等难点问题上取得进展。, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3wrgsNyr5lh6N2MY5xSnbvo4g5sRlc3MZoDdWpMeSdozUCPNhA96wndwQe3X5Z5oYMNxVUdOib63nw/0, createdBy=d8d11998754, createdName=Julie W, createdTime=Sun Jul 23 09:29:02 CST 2017, time=2017-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=225342, encodeId=baac22534296, content=根据疾病防治的实际需求,进一步加强国家临床医学研究中心按不同疾病种类和不同区域的布局建设,并对已建国家临床医学研究中心实施科学、规范管理,建立动态评估调整机制。, beContent=null, objectType=article, channel=null, level=null, likeNumber=14, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7cJ6ejWUr2nIia8qOvAKNdLHr32Df6G8iaoaOx6pHaoiacwp26DaslxZHCGbibZhhCGven4rvmWP60GahtzgFjgCjR/0, createdBy=6b111703011, createdName=有备才能无患, createdTime=Sun Jul 23 09:20:22 CST 2017, time=2017-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=225326, encodeId=c07422532675, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Sun Jul 23 08:38:33 CST 2017, time=2017-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=225302, encodeId=356022530281, content=好东西学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=92191944782, createdName=thlabcde, createdTime=Sun Jul 23 07:51:43 CST 2017, time=2017-07-23, status=1, ipAttribution=)]
    2017-07-24 131****2916

    不错的文章,值得学习

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1801140, encodeId=cd15180114056, content=<a href='/topic/show?id=76b5e3439fc' target=_blank style='color:#2F92EE;'>#研究能力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73439, encryptionId=76b5e3439fc, topicName=研究能力)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Wed Aug 16 19:33:00 CST 2017, time=2017-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=225950, encodeId=52cc225950fe, content=不错的文章,值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04f22055142, createdName=131****2916, createdTime=Mon Jul 24 22:40:32 CST 2017, time=2017-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1628939, encodeId=e16a162893961, content=<a href='/topic/show?id=c27a95e7106' target=_blank style='color:#2F92EE;'>#重大疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95771, encryptionId=c27a95e7106, topicName=重大疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c95421243926, createdName=雕雕, createdTime=Mon Jul 24 13:33:00 CST 2017, time=2017-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=225562, encodeId=a45222556203, content=不错的文章,值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04f22055142, createdName=131****2916, createdTime=Sun Jul 23 22:35:34 CST 2017, time=2017-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=225498, encodeId=f5c922549815, content=不错的文章,值得一看, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Sun Jul 23 16:29:22 CST 2017, time=2017-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=225365, encodeId=6a992253657e, content=中心建设不断延展, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/04/24/1c2dbd6706e64df33befd6663f1d6b37.jpg, createdBy=94f61661779, createdName=lyh994, createdTime=Sun Jul 23 09:44:30 CST 2017, time=2017-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=225353, encodeId=7ed022535371, content=自2012年以来,经过4年多的探索实践,我国重大疾病临床研究的“国家队”逐步形成。不仅在提升临床研究能力、加快临床转化方面取得实效,也在加速医药产品创新、系统性破解医疗服务供给不足等难点问题上取得进展。, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3wrgsNyr5lh6N2MY5xSnbvo4g5sRlc3MZoDdWpMeSdozUCPNhA96wndwQe3X5Z5oYMNxVUdOib63nw/0, createdBy=d8d11998754, createdName=Julie W, createdTime=Sun Jul 23 09:29:02 CST 2017, time=2017-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=225342, encodeId=baac22534296, content=根据疾病防治的实际需求,进一步加强国家临床医学研究中心按不同疾病种类和不同区域的布局建设,并对已建国家临床医学研究中心实施科学、规范管理,建立动态评估调整机制。, beContent=null, objectType=article, channel=null, level=null, likeNumber=14, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7cJ6ejWUr2nIia8qOvAKNdLHr32Df6G8iaoaOx6pHaoiacwp26DaslxZHCGbibZhhCGven4rvmWP60GahtzgFjgCjR/0, createdBy=6b111703011, createdName=有备才能无患, createdTime=Sun Jul 23 09:20:22 CST 2017, time=2017-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=225326, encodeId=c07422532675, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Sun Jul 23 08:38:33 CST 2017, time=2017-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=225302, encodeId=356022530281, content=好东西学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=92191944782, createdName=thlabcde, createdTime=Sun Jul 23 07:51:43 CST 2017, time=2017-07-23, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1801140, encodeId=cd15180114056, content=<a href='/topic/show?id=76b5e3439fc' target=_blank style='color:#2F92EE;'>#研究能力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73439, encryptionId=76b5e3439fc, topicName=研究能力)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Wed Aug 16 19:33:00 CST 2017, time=2017-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=225950, encodeId=52cc225950fe, content=不错的文章,值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04f22055142, createdName=131****2916, createdTime=Mon Jul 24 22:40:32 CST 2017, time=2017-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1628939, encodeId=e16a162893961, content=<a href='/topic/show?id=c27a95e7106' target=_blank style='color:#2F92EE;'>#重大疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95771, encryptionId=c27a95e7106, topicName=重大疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c95421243926, createdName=雕雕, createdTime=Mon Jul 24 13:33:00 CST 2017, time=2017-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=225562, encodeId=a45222556203, content=不错的文章,值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04f22055142, createdName=131****2916, createdTime=Sun Jul 23 22:35:34 CST 2017, time=2017-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=225498, encodeId=f5c922549815, content=不错的文章,值得一看, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Sun Jul 23 16:29:22 CST 2017, time=2017-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=225365, encodeId=6a992253657e, content=中心建设不断延展, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/04/24/1c2dbd6706e64df33befd6663f1d6b37.jpg, createdBy=94f61661779, createdName=lyh994, createdTime=Sun Jul 23 09:44:30 CST 2017, time=2017-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=225353, encodeId=7ed022535371, content=自2012年以来,经过4年多的探索实践,我国重大疾病临床研究的“国家队”逐步形成。不仅在提升临床研究能力、加快临床转化方面取得实效,也在加速医药产品创新、系统性破解医疗服务供给不足等难点问题上取得进展。, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3wrgsNyr5lh6N2MY5xSnbvo4g5sRlc3MZoDdWpMeSdozUCPNhA96wndwQe3X5Z5oYMNxVUdOib63nw/0, createdBy=d8d11998754, createdName=Julie W, createdTime=Sun Jul 23 09:29:02 CST 2017, time=2017-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=225342, encodeId=baac22534296, content=根据疾病防治的实际需求,进一步加强国家临床医学研究中心按不同疾病种类和不同区域的布局建设,并对已建国家临床医学研究中心实施科学、规范管理,建立动态评估调整机制。, beContent=null, objectType=article, channel=null, level=null, likeNumber=14, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7cJ6ejWUr2nIia8qOvAKNdLHr32Df6G8iaoaOx6pHaoiacwp26DaslxZHCGbibZhhCGven4rvmWP60GahtzgFjgCjR/0, createdBy=6b111703011, createdName=有备才能无患, createdTime=Sun Jul 23 09:20:22 CST 2017, time=2017-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=225326, encodeId=c07422532675, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Sun Jul 23 08:38:33 CST 2017, time=2017-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=225302, encodeId=356022530281, content=好东西学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=92191944782, createdName=thlabcde, createdTime=Sun Jul 23 07:51:43 CST 2017, time=2017-07-23, status=1, ipAttribution=)]
    2017-07-23 131****2916

    不错的文章,值得学习

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1801140, encodeId=cd15180114056, content=<a href='/topic/show?id=76b5e3439fc' target=_blank style='color:#2F92EE;'>#研究能力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73439, encryptionId=76b5e3439fc, topicName=研究能力)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Wed Aug 16 19:33:00 CST 2017, time=2017-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=225950, encodeId=52cc225950fe, content=不错的文章,值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04f22055142, createdName=131****2916, createdTime=Mon Jul 24 22:40:32 CST 2017, time=2017-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1628939, encodeId=e16a162893961, content=<a href='/topic/show?id=c27a95e7106' target=_blank style='color:#2F92EE;'>#重大疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95771, encryptionId=c27a95e7106, topicName=重大疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c95421243926, createdName=雕雕, createdTime=Mon Jul 24 13:33:00 CST 2017, time=2017-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=225562, encodeId=a45222556203, content=不错的文章,值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04f22055142, createdName=131****2916, createdTime=Sun Jul 23 22:35:34 CST 2017, time=2017-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=225498, encodeId=f5c922549815, content=不错的文章,值得一看, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Sun Jul 23 16:29:22 CST 2017, time=2017-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=225365, encodeId=6a992253657e, content=中心建设不断延展, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/04/24/1c2dbd6706e64df33befd6663f1d6b37.jpg, createdBy=94f61661779, createdName=lyh994, createdTime=Sun Jul 23 09:44:30 CST 2017, time=2017-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=225353, encodeId=7ed022535371, content=自2012年以来,经过4年多的探索实践,我国重大疾病临床研究的“国家队”逐步形成。不仅在提升临床研究能力、加快临床转化方面取得实效,也在加速医药产品创新、系统性破解医疗服务供给不足等难点问题上取得进展。, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3wrgsNyr5lh6N2MY5xSnbvo4g5sRlc3MZoDdWpMeSdozUCPNhA96wndwQe3X5Z5oYMNxVUdOib63nw/0, createdBy=d8d11998754, createdName=Julie W, createdTime=Sun Jul 23 09:29:02 CST 2017, time=2017-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=225342, encodeId=baac22534296, content=根据疾病防治的实际需求,进一步加强国家临床医学研究中心按不同疾病种类和不同区域的布局建设,并对已建国家临床医学研究中心实施科学、规范管理,建立动态评估调整机制。, beContent=null, objectType=article, channel=null, level=null, likeNumber=14, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7cJ6ejWUr2nIia8qOvAKNdLHr32Df6G8iaoaOx6pHaoiacwp26DaslxZHCGbibZhhCGven4rvmWP60GahtzgFjgCjR/0, createdBy=6b111703011, createdName=有备才能无患, createdTime=Sun Jul 23 09:20:22 CST 2017, time=2017-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=225326, encodeId=c07422532675, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Sun Jul 23 08:38:33 CST 2017, time=2017-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=225302, encodeId=356022530281, content=好东西学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=92191944782, createdName=thlabcde, createdTime=Sun Jul 23 07:51:43 CST 2017, time=2017-07-23, status=1, ipAttribution=)]
    2017-07-23 1e1b8538m79(暂无匿称)

    不错的文章,值得一看

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1801140, encodeId=cd15180114056, content=<a href='/topic/show?id=76b5e3439fc' target=_blank style='color:#2F92EE;'>#研究能力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73439, encryptionId=76b5e3439fc, topicName=研究能力)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Wed Aug 16 19:33:00 CST 2017, time=2017-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=225950, encodeId=52cc225950fe, content=不错的文章,值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04f22055142, createdName=131****2916, createdTime=Mon Jul 24 22:40:32 CST 2017, time=2017-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1628939, encodeId=e16a162893961, content=<a href='/topic/show?id=c27a95e7106' target=_blank style='color:#2F92EE;'>#重大疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95771, encryptionId=c27a95e7106, topicName=重大疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c95421243926, createdName=雕雕, createdTime=Mon Jul 24 13:33:00 CST 2017, time=2017-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=225562, encodeId=a45222556203, content=不错的文章,值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04f22055142, createdName=131****2916, createdTime=Sun Jul 23 22:35:34 CST 2017, time=2017-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=225498, encodeId=f5c922549815, content=不错的文章,值得一看, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Sun Jul 23 16:29:22 CST 2017, time=2017-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=225365, encodeId=6a992253657e, content=中心建设不断延展, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/04/24/1c2dbd6706e64df33befd6663f1d6b37.jpg, createdBy=94f61661779, createdName=lyh994, createdTime=Sun Jul 23 09:44:30 CST 2017, time=2017-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=225353, encodeId=7ed022535371, content=自2012年以来,经过4年多的探索实践,我国重大疾病临床研究的“国家队”逐步形成。不仅在提升临床研究能力、加快临床转化方面取得实效,也在加速医药产品创新、系统性破解医疗服务供给不足等难点问题上取得进展。, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3wrgsNyr5lh6N2MY5xSnbvo4g5sRlc3MZoDdWpMeSdozUCPNhA96wndwQe3X5Z5oYMNxVUdOib63nw/0, createdBy=d8d11998754, createdName=Julie W, createdTime=Sun Jul 23 09:29:02 CST 2017, time=2017-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=225342, encodeId=baac22534296, content=根据疾病防治的实际需求,进一步加强国家临床医学研究中心按不同疾病种类和不同区域的布局建设,并对已建国家临床医学研究中心实施科学、规范管理,建立动态评估调整机制。, beContent=null, objectType=article, channel=null, level=null, likeNumber=14, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7cJ6ejWUr2nIia8qOvAKNdLHr32Df6G8iaoaOx6pHaoiacwp26DaslxZHCGbibZhhCGven4rvmWP60GahtzgFjgCjR/0, createdBy=6b111703011, createdName=有备才能无患, createdTime=Sun Jul 23 09:20:22 CST 2017, time=2017-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=225326, encodeId=c07422532675, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Sun Jul 23 08:38:33 CST 2017, time=2017-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=225302, encodeId=356022530281, content=好东西学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=92191944782, createdName=thlabcde, createdTime=Sun Jul 23 07:51:43 CST 2017, time=2017-07-23, status=1, ipAttribution=)]
    2017-07-23 lyh994

    中心建设不断延展

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1801140, encodeId=cd15180114056, content=<a href='/topic/show?id=76b5e3439fc' target=_blank style='color:#2F92EE;'>#研究能力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73439, encryptionId=76b5e3439fc, topicName=研究能力)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Wed Aug 16 19:33:00 CST 2017, time=2017-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=225950, encodeId=52cc225950fe, content=不错的文章,值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04f22055142, createdName=131****2916, createdTime=Mon Jul 24 22:40:32 CST 2017, time=2017-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1628939, encodeId=e16a162893961, content=<a href='/topic/show?id=c27a95e7106' target=_blank style='color:#2F92EE;'>#重大疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95771, encryptionId=c27a95e7106, topicName=重大疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c95421243926, createdName=雕雕, createdTime=Mon Jul 24 13:33:00 CST 2017, time=2017-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=225562, encodeId=a45222556203, content=不错的文章,值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04f22055142, createdName=131****2916, createdTime=Sun Jul 23 22:35:34 CST 2017, time=2017-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=225498, encodeId=f5c922549815, content=不错的文章,值得一看, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Sun Jul 23 16:29:22 CST 2017, time=2017-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=225365, encodeId=6a992253657e, content=中心建设不断延展, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/04/24/1c2dbd6706e64df33befd6663f1d6b37.jpg, createdBy=94f61661779, createdName=lyh994, createdTime=Sun Jul 23 09:44:30 CST 2017, time=2017-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=225353, encodeId=7ed022535371, content=自2012年以来,经过4年多的探索实践,我国重大疾病临床研究的“国家队”逐步形成。不仅在提升临床研究能力、加快临床转化方面取得实效,也在加速医药产品创新、系统性破解医疗服务供给不足等难点问题上取得进展。, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3wrgsNyr5lh6N2MY5xSnbvo4g5sRlc3MZoDdWpMeSdozUCPNhA96wndwQe3X5Z5oYMNxVUdOib63nw/0, createdBy=d8d11998754, createdName=Julie W, createdTime=Sun Jul 23 09:29:02 CST 2017, time=2017-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=225342, encodeId=baac22534296, content=根据疾病防治的实际需求,进一步加强国家临床医学研究中心按不同疾病种类和不同区域的布局建设,并对已建国家临床医学研究中心实施科学、规范管理,建立动态评估调整机制。, beContent=null, objectType=article, channel=null, level=null, likeNumber=14, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7cJ6ejWUr2nIia8qOvAKNdLHr32Df6G8iaoaOx6pHaoiacwp26DaslxZHCGbibZhhCGven4rvmWP60GahtzgFjgCjR/0, createdBy=6b111703011, createdName=有备才能无患, createdTime=Sun Jul 23 09:20:22 CST 2017, time=2017-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=225326, encodeId=c07422532675, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Sun Jul 23 08:38:33 CST 2017, time=2017-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=225302, encodeId=356022530281, content=好东西学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=92191944782, createdName=thlabcde, createdTime=Sun Jul 23 07:51:43 CST 2017, time=2017-07-23, status=1, ipAttribution=)]
    2017-07-23 Julie W

    自2012年以来,经过4年多的探索实践,我国重大疾病临床研究的“国家队”逐步形成。不仅在提升临床研究能力、加快临床转化方面取得实效,也在加速医药产品创新、系统性破解医疗服务供给不足等难点问题上取得进展。

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1801140, encodeId=cd15180114056, content=<a href='/topic/show?id=76b5e3439fc' target=_blank style='color:#2F92EE;'>#研究能力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73439, encryptionId=76b5e3439fc, topicName=研究能力)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Wed Aug 16 19:33:00 CST 2017, time=2017-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=225950, encodeId=52cc225950fe, content=不错的文章,值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04f22055142, createdName=131****2916, createdTime=Mon Jul 24 22:40:32 CST 2017, time=2017-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1628939, encodeId=e16a162893961, content=<a href='/topic/show?id=c27a95e7106' target=_blank style='color:#2F92EE;'>#重大疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95771, encryptionId=c27a95e7106, topicName=重大疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c95421243926, createdName=雕雕, createdTime=Mon Jul 24 13:33:00 CST 2017, time=2017-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=225562, encodeId=a45222556203, content=不错的文章,值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04f22055142, createdName=131****2916, createdTime=Sun Jul 23 22:35:34 CST 2017, time=2017-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=225498, encodeId=f5c922549815, content=不错的文章,值得一看, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Sun Jul 23 16:29:22 CST 2017, time=2017-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=225365, encodeId=6a992253657e, content=中心建设不断延展, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/04/24/1c2dbd6706e64df33befd6663f1d6b37.jpg, createdBy=94f61661779, createdName=lyh994, createdTime=Sun Jul 23 09:44:30 CST 2017, time=2017-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=225353, encodeId=7ed022535371, content=自2012年以来,经过4年多的探索实践,我国重大疾病临床研究的“国家队”逐步形成。不仅在提升临床研究能力、加快临床转化方面取得实效,也在加速医药产品创新、系统性破解医疗服务供给不足等难点问题上取得进展。, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3wrgsNyr5lh6N2MY5xSnbvo4g5sRlc3MZoDdWpMeSdozUCPNhA96wndwQe3X5Z5oYMNxVUdOib63nw/0, createdBy=d8d11998754, createdName=Julie W, createdTime=Sun Jul 23 09:29:02 CST 2017, time=2017-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=225342, encodeId=baac22534296, content=根据疾病防治的实际需求,进一步加强国家临床医学研究中心按不同疾病种类和不同区域的布局建设,并对已建国家临床医学研究中心实施科学、规范管理,建立动态评估调整机制。, beContent=null, objectType=article, channel=null, level=null, likeNumber=14, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7cJ6ejWUr2nIia8qOvAKNdLHr32Df6G8iaoaOx6pHaoiacwp26DaslxZHCGbibZhhCGven4rvmWP60GahtzgFjgCjR/0, createdBy=6b111703011, createdName=有备才能无患, createdTime=Sun Jul 23 09:20:22 CST 2017, time=2017-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=225326, encodeId=c07422532675, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Sun Jul 23 08:38:33 CST 2017, time=2017-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=225302, encodeId=356022530281, content=好东西学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=92191944782, createdName=thlabcde, createdTime=Sun Jul 23 07:51:43 CST 2017, time=2017-07-23, status=1, ipAttribution=)]
    2017-07-23 有备才能无患

    根据疾病防治的实际需求,进一步加强国家临床医学研究中心按不同疾病种类和不同区域的布局建设,并对已建国家临床医学研究中心实施科学、规范管理,建立动态评估调整机制。

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1801140, encodeId=cd15180114056, content=<a href='/topic/show?id=76b5e3439fc' target=_blank style='color:#2F92EE;'>#研究能力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73439, encryptionId=76b5e3439fc, topicName=研究能力)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Wed Aug 16 19:33:00 CST 2017, time=2017-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=225950, encodeId=52cc225950fe, content=不错的文章,值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04f22055142, createdName=131****2916, createdTime=Mon Jul 24 22:40:32 CST 2017, time=2017-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1628939, encodeId=e16a162893961, content=<a href='/topic/show?id=c27a95e7106' target=_blank style='color:#2F92EE;'>#重大疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95771, encryptionId=c27a95e7106, topicName=重大疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c95421243926, createdName=雕雕, createdTime=Mon Jul 24 13:33:00 CST 2017, time=2017-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=225562, encodeId=a45222556203, content=不错的文章,值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04f22055142, createdName=131****2916, createdTime=Sun Jul 23 22:35:34 CST 2017, time=2017-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=225498, encodeId=f5c922549815, content=不错的文章,值得一看, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Sun Jul 23 16:29:22 CST 2017, time=2017-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=225365, encodeId=6a992253657e, content=中心建设不断延展, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/04/24/1c2dbd6706e64df33befd6663f1d6b37.jpg, createdBy=94f61661779, createdName=lyh994, createdTime=Sun Jul 23 09:44:30 CST 2017, time=2017-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=225353, encodeId=7ed022535371, content=自2012年以来,经过4年多的探索实践,我国重大疾病临床研究的“国家队”逐步形成。不仅在提升临床研究能力、加快临床转化方面取得实效,也在加速医药产品创新、系统性破解医疗服务供给不足等难点问题上取得进展。, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3wrgsNyr5lh6N2MY5xSnbvo4g5sRlc3MZoDdWpMeSdozUCPNhA96wndwQe3X5Z5oYMNxVUdOib63nw/0, createdBy=d8d11998754, createdName=Julie W, createdTime=Sun Jul 23 09:29:02 CST 2017, time=2017-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=225342, encodeId=baac22534296, content=根据疾病防治的实际需求,进一步加强国家临床医学研究中心按不同疾病种类和不同区域的布局建设,并对已建国家临床医学研究中心实施科学、规范管理,建立动态评估调整机制。, beContent=null, objectType=article, channel=null, level=null, likeNumber=14, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7cJ6ejWUr2nIia8qOvAKNdLHr32Df6G8iaoaOx6pHaoiacwp26DaslxZHCGbibZhhCGven4rvmWP60GahtzgFjgCjR/0, createdBy=6b111703011, createdName=有备才能无患, createdTime=Sun Jul 23 09:20:22 CST 2017, time=2017-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=225326, encodeId=c07422532675, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Sun Jul 23 08:38:33 CST 2017, time=2017-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=225302, encodeId=356022530281, content=好东西学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=92191944782, createdName=thlabcde, createdTime=Sun Jul 23 07:51:43 CST 2017, time=2017-07-23, status=1, ipAttribution=)]
    2017-07-23 Y—xianghai

    学习了新知识

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=1801140, encodeId=cd15180114056, content=<a href='/topic/show?id=76b5e3439fc' target=_blank style='color:#2F92EE;'>#研究能力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73439, encryptionId=76b5e3439fc, topicName=研究能力)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Wed Aug 16 19:33:00 CST 2017, time=2017-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=225950, encodeId=52cc225950fe, content=不错的文章,值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04f22055142, createdName=131****2916, createdTime=Mon Jul 24 22:40:32 CST 2017, time=2017-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1628939, encodeId=e16a162893961, content=<a href='/topic/show?id=c27a95e7106' target=_blank style='color:#2F92EE;'>#重大疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95771, encryptionId=c27a95e7106, topicName=重大疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c95421243926, createdName=雕雕, createdTime=Mon Jul 24 13:33:00 CST 2017, time=2017-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=225562, encodeId=a45222556203, content=不错的文章,值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04f22055142, createdName=131****2916, createdTime=Sun Jul 23 22:35:34 CST 2017, time=2017-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=225498, encodeId=f5c922549815, content=不错的文章,值得一看, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Sun Jul 23 16:29:22 CST 2017, time=2017-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=225365, encodeId=6a992253657e, content=中心建设不断延展, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/04/24/1c2dbd6706e64df33befd6663f1d6b37.jpg, createdBy=94f61661779, createdName=lyh994, createdTime=Sun Jul 23 09:44:30 CST 2017, time=2017-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=225353, encodeId=7ed022535371, content=自2012年以来,经过4年多的探索实践,我国重大疾病临床研究的“国家队”逐步形成。不仅在提升临床研究能力、加快临床转化方面取得实效,也在加速医药产品创新、系统性破解医疗服务供给不足等难点问题上取得进展。, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3wrgsNyr5lh6N2MY5xSnbvo4g5sRlc3MZoDdWpMeSdozUCPNhA96wndwQe3X5Z5oYMNxVUdOib63nw/0, createdBy=d8d11998754, createdName=Julie W, createdTime=Sun Jul 23 09:29:02 CST 2017, time=2017-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=225342, encodeId=baac22534296, content=根据疾病防治的实际需求,进一步加强国家临床医学研究中心按不同疾病种类和不同区域的布局建设,并对已建国家临床医学研究中心实施科学、规范管理,建立动态评估调整机制。, beContent=null, objectType=article, channel=null, level=null, likeNumber=14, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7cJ6ejWUr2nIia8qOvAKNdLHr32Df6G8iaoaOx6pHaoiacwp26DaslxZHCGbibZhhCGven4rvmWP60GahtzgFjgCjR/0, createdBy=6b111703011, createdName=有备才能无患, createdTime=Sun Jul 23 09:20:22 CST 2017, time=2017-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=225326, encodeId=c07422532675, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Sun Jul 23 08:38:33 CST 2017, time=2017-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=225302, encodeId=356022530281, content=好东西学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=92191944782, createdName=thlabcde, createdTime=Sun Jul 23 07:51:43 CST 2017, time=2017-07-23, status=1, ipAttribution=)]
    2017-07-23 thlabcde

    好东西学习了!

    0

相关资讯

Neovii:临床研究长期结果有力支持Grafalon(R)成为标准疗法

无亲戚关系匹配捐赠者造血细胞移植标准GvHD预防后的长期结果有力支持Grafalon®成为标准疗法

JAMA:美国国家科学院人类基因编辑原则

美国国家科学院报告对与人类基因组编辑相关的专业设置、编辑监督与应用提出建议

Crit Care Med:急性呼吸衰竭幸存者临床研究的核心领域

确定利益相关者认同的“核心领域”对于考察所有急性呼吸衰竭幸存者出院后结局评价临床研究而言是必不可少的。2017年6月,发表在《Crit Care Med》的一项研究调查了急性呼吸衰竭幸存者临床研究的核心领域。

Lancet Oncol:PD-1免疫治疗药物能有效治疗恶性胸膜间皮瘤 (KEYNOTE-028)

现有的称为彭博瑞珠单抗的免疫治疗药物似乎有效治疗恶性胸膜间皮瘤,这是一种罕见且侵袭性的肺癌,主要是由暴露于石棉引起的。在“柳叶刀肿瘤学”杂志上,研究人员描述了使用抗体药物对这种罕见癌症的阳性结果的第一项研究。医生检查胸部 X 光片研究结果表明,免疫治疗药物显示出对恶性胸膜间皮瘤的二线治疗有希望,这是一种由暴露于石棉导致的罕见和侵袭性肺癌。

西安交大二附院临床研究在美国引广泛关注

记者近日从西安交通大学第二附属医院获悉,西安交大二附院等联合开展的CAR-T治疗多发性骨髓瘤研究在美国临床肿瘤学会年会上引起广泛关注。这项研究的作者、西安交通大学第二附属医院的赵万红教授在一年一度的国际肿瘤学界盛会——美国临床肿瘤学会(ASCO)年会上介绍这项取得显着疗效的新型免疫治疗研究说,CAR-T是一种患者定制式治疗,即收集患者自身的T细胞,在体外进行基因重组,再回输到患者体内。基因重组的过

Ann Intern Med:中医方剂随机对照试验报告国际标准(CONSORT CHM formula 2017)制定——共同提升中医方剂临床研究水平

2017年6月27日是一个值得纪念的日子。中医方剂随机对照试验报告国际标准当日通过美国《内科学年鉴》正式向全球发布,以简体中文、繁体中文、英文三种文字同期发表,并配发编者社论。该标准历时十年余,由中国、加拿大、英国学者组成的国际核心团队共同完成,包括香港浸会大学协理副校长、中医药学院临床部主任、我分会副会长卞兆祥教授,四川大学华西医院、我分会顾问李幼平教授、吴泰相副教授,北京中医药大学东直门医院、